(NYSE: RDY) Dr Reddys Laboratories's forecast annual revenue growth rate of 2.87% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.92%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.7%.
Dr Reddys Laboratories's revenue in 2025 is $3,785,730,898.On average, 2 Wall Street analysts forecast RDY's revenue for 2026 to be $3,255,318,858,062, with the lowest RDY revenue forecast at $3,227,206,056,816, and the highest RDY revenue forecast at $3,283,431,659,309. On average, 2 Wall Street analysts forecast RDY's revenue for 2027 to be $3,265,211,326,415, with the lowest RDY revenue forecast at $3,225,328,532,244, and the highest RDY revenue forecast at $3,305,094,120,585.
In 2028, RDY is forecast to generate $3,471,142,393,666 in revenue, with the lowest revenue forecast at $3,430,229,047,120 and the highest revenue forecast at $3,512,055,740,212.